FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
Question
FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
Direct answer
Commercial authorization of RASONQUE establishes first-line commercial oncology cash flows for RVMD through specialized specialty pharmacy distribution networks. — bullish pressure on RVMD via oncology product commercial revenue realization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-27
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer”, revision 1, evidence through 2026-08-27. https://marketontology.com/catalysts/2026-08-27/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-3d3b3a
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| RVMD | ▲Bull | 1–3 months | oncology product commercial revenue realization | 78 |
FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
Commercial authorization of RASONQUE establishes first-line commercial oncology cash flows for RVMD through specialized specialty pharmacy distribution networks. — bullish pressure on RVMD via oncology product commercial revenue realization.
FDA approved RASONQUE for metastatic pancreatic adenocarcinoma based on Phase 3 trial.
- SourceFDA approved RASONQUE for metastatic pancreatic adenocarcinoma based on Phase 3 trial.
- TransmissionCommercial authorization of RASONQUE establishes first-line commercial oncology cash flows for RVMD through specialized specialty pharmacy distribution networks.
- SummaryFDA grants approval for Revolution Medicines' daraxonrasib in pretreated metastatic pancreatic cancer. Pivotal Phase 3 data forms the basis of the approval with Onco360 appointed as national dispensing partner. The greenlight establishes the first broad RAS-targeted treatment option in this oncology indication.
- RVMDDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- RVMD closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- RVMD price vs. pre-event level
- RVMD volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib) · Polygon News · 2026-08-26
Related catalysts
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer DataRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung CancerRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.